Trial of efficiency of Cymelarsan™ on Trypanosoma evansi in camel

Abstract

The experimentation in Niger of a new arsenical molecule for the treatment of camel trypanosomiasis by Trypanosoma evansi showed, during the effectiveness trial undertaken on eight young carnets (Camelus dromedarius) artificially infested with Trypanosoma evansi, a full trypanocidal effect of the drug at the two doses used (0.625 mg/kg and 1.250 mg/kg). The general and local tolerances were satisfactory at the lower dose. At a dose of 3.75 mg/kg (toxicity trial) the drug induced a significant necrosis of the tissues at the point of inoculation whether the injection was subcutaneous or intramuscular.